Sandbox:M.Romo

Eculizumab (Soliris) is a fully humanized IgG2/IgG4 monoclonal antibody that inhibits the terminal complement protein C5, preventing its cleavage into C5a (proinflammatory) and C5b (membrane attack complex coordinator). Eculizumab is known to be effective in reducing the frequency of relapse in highly clinically active, AQP4-IgG–positive disease. It provided the first FDA-approved treatment for neuromyelitis optica spectrum disorder (NMOSD), which has drastically changed the natural history of patients with NMOSD.

While the survival benefit of Solaris in NMOSD is undeniable, as occurs with all proteins, there is a potential for immunogenicity. Surprisingly, very few cases of lupus reactivation have been reported, and by literature review using PubMed and MEDLINE using discoid lupus and/or eculizumab, cero case-reports were retrieved. Among the most common adverse effects of Soliris reported are high blood pressure and headache. Only 1-10% report anaphylactic reaction and 10-15% experiment rash.